For Institutions
About
The California Public Utilities Commission is poised to approve Verizon's $20 billion acquisition of Frontier Communications. This follows Verizon's agreement to certain conditions, including the termination of its diversity programs, which had raised concerns. The deal, initially announced in September 2024, involves Verizon purchasing Frontier for approximately $9.6 billion and taking on $10 billion in debt. Verizon plans to enhance Frontier's network across 25 states and aims to deploy fiber to over 1 million homes annually.
Lockheed Martin Corporation has successfully completed the first flight test of its Next-Generation Short-Range Interceptor (NGSRI), a potential replacement for the Stinger missile. Conducted at the U.S. Army White Sands Missile Range, the test validated the interceptor’s performance and marked a significant milestone. The NGSRI is designed to counter threats from unmanned aerial systems and aircraft, reportedly doubling the capability of the legacy system. The project advanced from concept to flight in just 26 months, utilizing advanced technologies like AI and machine learning.
Global drugmakers are increasing U.S. manufacturing and stockpiling inventory in response to a potential 100% tariff on imported medicines. Companies like Pfizer, Eli Lilly, and Johnson & Johnson are committing billions to expand U.S. operations and secure tariff exemptions. Pfizer plans a $70 billion investment, while AstraZeneca and Roche are investing $50 billion each. Other firms, including Novartis and Sanofi, are also making significant investments to mitigate supply-chain risks and reassure investors amid tariff threats.
At the J.P. Morgan Healthcare Conference 2026, Gilead's CEO Daniel O’Day highlighted the company's competitive advantage in HIV treatment with seven pipeline drugs. Gilead's offerings include various dosing options for both treatment and prevention, such as the recently launched Yeztugo, which achieved $150 million in sales in 2025. The company anticipates significant growth in the HIV market, with a forecasted increase from $26.5 billion in 2023 to $32.1 billion by 2033, driven by innovative therapies and expanding access in regions like sub-Saharan Africa.
Merck has raised its revenue outlook to $70 billion by the mid-2030s, signaling renewed confidence despite the impending loss of its Keytruda patent, which could impact 50% of its revenue. Analysts from Bernstein, BMO Capital Markets, and Citi provided mixed reviews, with Bernstein highlighting the challenges ahead, while BMO noted a newfound confidence in Merck's strategy. Citi acknowledged progress but cautioned that Merck is not yet fully secure against the patent loss's effects.
